Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript March 5, 2026 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07.
FDA PMA establishes Claire as the first AI-integrated imaging device indicated for real-time intraoperative margin assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results